NKGen Biotech, Inc. Common Stock
NKGN
NKGN was delisted on the 4th of March, 2025.
17 hedge funds and large institutions have $4.24M invested in NKGen Biotech, Inc. Common Stock in 2024 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 2 closing their positions.
200% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 2
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
31% more funds holding
Funds holding: 13 → 17 (+4)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
25% less capital invested
Capital invested by funds: $5.66M → $4.24M (-$1.42M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DC
Diametric Capital
Boston,
Massachusetts
|
+$466K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$45.7K |
| 3 |
VF
Virtu Financial
New York
|
+$26.4K |
| 4 |
BlackRock
New York
|
+$23.7K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$21.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MC
Meteora Capital
Boca Raton,
Florida
|
-$55.4K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$32K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.31K |
| 4 |
Wells Fargo
San Francisco,
California
|
-$91 |
NKGN Hedge Fund Activity: Q2 2024 in Review
17 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in NKGen Biotech, Inc. Common Stock (NKGN) for Q2 2024, worth a combined $4.24M — down 25% from $5.66M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new NKGN positions and 2 closed out — a net gain of 4 holders — while 4 added to existing stakes and 2 trimmed.
The largest buyer was Diametric Capital, opening a new position worth an estimated $466K. The largest seller was Meteora Capital, cutting an estimated $55.4K.
- 17 institutional investors held NKGen Biotech, Inc. Common Stock (NKGN) as of Q2 2024, up from 13 in Q1 2024.
- Funds reported $4.24M of NKGen Biotech, Inc. Common Stock stock for Q2 2024, down 25% quarter-over-quarter.
- 6 funds opened new NKGen Biotech, Inc. Common Stock positions in Q2 2024 and 2 closed out, a net change of +4 holders.
- The largest NKGen Biotech, Inc. Common Stock buyer in Q2 2024 was Diametric Capital, an estimated $466K added.
- The largest NKGen Biotech, Inc. Common Stock seller in Q2 2024 was Meteora Capital, an estimated $55.4K sold.
Based on aggregated 13F filings for Q2 2024.